Companies / NOX

NOXOPHARM LIMITED

ASX:NOXPharmaceuticals, Biotechnology & Life Sciences
307.2M shares on issueASX (delayed) · as of 28 July 2026$0.082price · delayed$27.3Mmarket cap · indicative
B
Dilution grade

Runway under 2 quarters

Cash runway0.0 quarters of funding
Share-count growth (24m)0.0%no issuance filings since 2024
Raise cadence (24m)0 cash raises
Options & rights overhang1.7% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

NOXOPHARM LIMITED listed in August 2016; its disclosure history includes no new share-issuance (Appendix 2A) filings lodged since January 2024. The company's ordinary share count stood at 307M as of February 2026 (latest available, one observation). There were no capital raises in the 24‑month window. Options and rights on issue could convert into 5M new shares, equal to 1.7% of the current share count, with 0% in the money and the nearest expiry in September 2027. At the June 2026 quarter the company reported A$26K in cash, representing 0.0 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
1.7%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
0.0 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 307.2M per ASX (delayed) (28 July 2026).
295.4M299.7M304.1MDec 24Sept 25July 26

Cash runway

0.0 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$26k available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
26 Feb 20262A · quoted issueNOX : ORDINARY FULLY PAID307.2MAppendix 2A
1 Jan 20263G · unquotedORDINARY FULLY PAID292.2MAppendix 3G
1 Jan 20263H · cancellationNOX : ORDINARY FULLY PAID292.2MAppendix 3H
11 Dec 20253G · unquotedORDINARY FULLY PAID292.2MAppendix 3G
10 Jan 20253G · unquotedNOX : ORDINARY FULLY PAID292.2MAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

1.7%
Total overhang · of current shares
0.0%
In the money · at current price
5.1M
Potential new shares
Sept 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
25 May 2026Boris PatkinOther——$38k3Y notice
12 Dec 2025Fred BartOther—250k$1.3M3Y notice
6 Nov 2024Gisela MautnerSell—135k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

21 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
6 July 2026Pre-IND meeting request with US FDA
1 July 2026Sofr platform versatility shown via childbirth MRFF grant
30 June 2026Fast-tracking of cancer program via novel animal model
8 June 2026$PSOF-SKN manufacturing begins to ensure clinical trial readi
1 June 2026Change of Director's Interest Notice
25 May 2026$PNew data confirms cancer-fighting potential
19 May 2026$PNoxopharms Sofra assets to be presented at global conference
7 May 2026Proposed issue of securities - NOX
5 May 2026$PNoxopharm progresses US regulatory strategy
30 Apr 2026$PNew data shows SOF-SKN active ingredient efficacy
29 Apr 2026New Company Secretary appointed
26 Apr 2026$PInnovative collaboration further expands Sofra platform
23 Apr 2026$PMarch 2026 Quarterly Activities Report and Appendix 4C
21 Apr 2026$PPositive SOF-SKN dosing data shows prolonged skin retention
14 Apr 2026$PNoxopharm appoints Dr Olivier Laczka as new CEO
14 Apr 2026Change of & Final Directors Interest Notice (App 3Y & 3Z)-GM
13 Apr 2026$PResignation of Chief Executive Officer
27 Feb 2026$PAppendix 4D and FY2026 Half Year Financial Report
26 Feb 2026Notice under Section 708A(5)(e) of the Corps Act

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.